Navigation Links
Pappas Ventures Promotes Scott Weiner to Partner

RESEARCH TRIANGLE PARK, N.C., Jan. 8, 2014 /PRNewswire/ --  Pappas Ventures, a life science venture capital firm, announced today that Scott Weiner, who joined the firm in 2006, has been promoted to Partner.

"We are pleased to recognize Scott's many contributions to the development and success of our firm," said Art Pappas, Managing Partner at Pappas Ventures. "His knowledge of the life sciences industry and broad transaction experience is valued immensely both by my Pappas colleagues and by our many portfolio companies."

Among the many Pappas Ventures portfolio companies with which Mr. Weiner has been involved, he played a key role in the firm's successful investments in TESARO,  Achillion Pharmaceuticals and Athersys. He currently serves as a director for Gentis and Milestone Pharmaceuticals, and as an observer for IlluminOss Medical, Liquidia Technologies and Thrasos Therapeutics.

Before joining Pappas Ventures as a Principal, he was with Silverback Asset Management's life science fund where he focused on healthcare securities investing. Prior to Silverback, he spent three years at Chicago Growth Partners (formerly William Blair Capital Partners) as a Vice President focusing on healthcare venture capital investments. Previously, he spent three and a half years in investment banking at Lehman Brothers, where he worked in the healthcare group in New York covering biotechnology, medical devices and drug delivery; the financial sponsors/leveraged finance group in London, and the media/telecom group in Hong Kong.

Mr. Weiner earned a Bachelor of Science in biological anthropology and anatomy from Duke University and a Master of Business Administration from Duke University's Fuqua School of Business.

About Pappas Ventures

Founded in 1994, Pappas Ventures invests exclusively in the life sciences sector – biotechnology, biopharmaceuticals, drug delivery, medical devices and related ventures – across the United States and Canada. On January 6, 2014, Medtronic announced that it had acquired Pappas Ventures portfolio company TYRX for $160 million plus performance-based milestone payments. TYRX is the fourth Pappas Ventures portfolio company to either go public or be sold in the past 18 months.

Pappas Ventures has more than $350 million in capital under management, and has guided the launch and/or development of 56 companies, including Plexxikon Inc. (acquired by Daiichi Sankyo), Cerexa (acquired by Forest Laboratories), Peninsula Pharmaceuticals (acquired by Johnson & Johnson), Syntonix (acquired by Biogen IDEC), LEAD Therapeutics (acquired by BioMarin Pharmaceutical), Chimerix (IPO), TESARO (IPO), NuVasive (IPO) and Arena Pharmaceuticals (IPO). For more information about Pappas Ventures, please visit

Ford S. Worthy 

SOURCE Pappas Ventures
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pappas Ventures Names Pat Gage to Scientific Advisory Board
2. Sunpeaks Ventures Files Defamation Lawsuit
3. Practice Fusion Announces $34 Million in Financing Led by Artis Ventures
4. SJF Ventures Completes Oversubscribed Series A Round for BioSurplus
5. Sunpeaks Ventures Announces Second Quarter 2012 Results
6. Thesan Pharmaceuticals Announces Series A Funding Co-Led By Novo Ventures And Novartis Venture Funds
7. Thesan Pharmaceuticals gibt Serie-A-Finanzierung unter gemeinsamer Führung von Novo Ventures und Novartis Venture Funds bekannt
8. Thesan Pharmaceuticals annuncia un finanziamento di serie A co-gestito da Novo Ventures e Novartis Venture Funds
9. Thesan Pharmaceuticals offentliggør første runde af venturefinansieringen ledt af Novo Ventures og Novartis Venture Funds i fællesskab
10. Market Boosted by Strong Tech Earnings: Bank of America Corp., MAP Pharmaceuticals Inc., Swingplane Ventures Inc., World Moto, Inc., Organovo Holdings, Inc.
11. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
Post Your Comments:
(Date:11/26/2015)... 2015 --> ... combineert immunotherapie met Bremachlorin-photodynamische therapie voor de ... ) --> ... ) Uit een ... (LUMC) blijkt dat ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Therapeutic Drug Monitoring (TDM) Market: Supplier ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare ... participated in the 61st annual Employee Benefits Conference. The Employee Benefits Conference was ... November 8th through Wednesday, November 11th, 2015. The conference was held at the ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... has collaborated with Women’s Web – an online resource for Indian women ... mental and emotional well-being relationship, life balance, stress, professional development, and lifestyle. ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... more aggressive than those found on mammography, according to a study published online ... additional cancers not seen on mammography may necessitate a change in treatment. , ...
(Date:11/25/2015)... ... November 25, 2015 , ... The holiday season ... and pleasing the palates of attendees is of the utmost importance. Whether you ... seasonal get-together, give these recipes a try this holiday season. , Turkey Croquettes ...
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, one ... for its stellar workplace culture with the company’s Cincinnati office being named a ... Cincinnati office was named a finalist in Cincinnati Business Courier’s 13th annual Greater ...
Breaking Medicine News(10 mins):